<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28401075</article-id><article-id pub-id-type="pmc">5360001</article-id><article-id pub-id-type="publisher-id">ABR-6-28</article-id><article-id pub-id-type="doi">10.4103/2277-9175.201685</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shahvazian</surname><given-names>Najmeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rafiee</surname><given-names>Mansour</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rahmanian</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Razavi-ratki</surname><given-names>Seyed Kazem</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Farahzadi</surname><given-names>Mohammad Hadi</given-names></name><xref ref-type="aff" rid="aff4">3</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><italic>From the Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran</italic></aff><aff id="aff2"><label>1</label><italic>Department of Endocrinology and Metabolism, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran</italic></aff><aff id="aff3"><label>2</label><italic>Department of Nuclear Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran</italic></aff><aff id="aff4"><label>3</label><italic>Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence:</bold> Dr. Mohammad Hadi Farahzadi, Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. E-mail: <email xlink:href="dr.farahzadi@yahoo.com">dr.farahzadi@yahoo.com</email></italic></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>07</day><month>3</month><year>2017</year></pub-date><volume>6</volume><elocation-id>28</elocation-id><history><date date-type="received"><month>6</month><year>2015</year></date><date date-type="accepted"><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Advanced Biomedical Research</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Remote ischemic preconditioning (RIPC) is a phenomenon where a short period of ischemia in one organ protects against further ischemia in the other organs. We hypothesized that RIPC occurring in diabetic patients with ankle brachial index (ABI) between 0.70 and 0.90 were included with peripheral arterial disease, would make the better coronary flow resulted in the increasing ABI.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This randomized clinical trial study was done in the Afshar Cardiovascular Hospital in Yazd between 2013 and 2014. Sixty participants were randomly divided into two groups (intervention and control groups). The intervention group was undergoing RIPC, and the control group was tested without RIPC. RIPC was stimulated by giving three cycles of 5 min of ischemia followed by 5 min of reperfusion of both upper arms using a blood pressure cuff inflated to 200 mm Hg (<italic>n</italic> = 30). This was compared with no RIPC group which consisted of placing a deflated blood pressure cuff on the upper limbs (<italic>n</italic> = 30).</p></sec><sec id="st3"><title>Results:</title><p>The mean of ABI level before intervention in the RIPC and control group group was 0.82 &#x000b1; 0.055 and 0.83 &#x000b1; 0.0603 (<italic>P</italic> = 0.347) respectively, with no significant difference. It was 0.86 &#x000b1; 0.066 in the RIPC group compared the control 0.83 &#x000b1; 0.0603 (<italic>P</italic> = 0.046). So levels of ABI were greater after intervention in the RIPC group. The mean of ABI level increase from 0.82 &#x000b1; 0.05 to 0.86 &#x000b1; 0.06 in RIPC group (<italic>P</italic> = 0.008). So the intervention group showed a significant increase in ABI.</p></sec><sec id="st4"><title>Conclusions:</title><p>RIPC through using a simple, noninvasive technique, composing three cycles of 5 min-ischemia of both upper arms, showing a significant increase in ABI level in diabetic patients.</p></sec></abstract><kwd-group><kwd><italic>Ankle brachial index</italic></kwd><kwd><italic>peripheral arterial disease</italic></kwd><kwd><italic>remote ischemic preconditioning</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Peripheral arterial disease (PAD) is found in approximately 60% of patients with coronary artery disease.[<xref rid="ref1" ref-type="bibr">1</xref>] Coronary heart disease is the leading cause of morbidity and mortality in the worldwide.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>PAD, as an ankle brachial index (ABI) of &#x0003c;0.9, increases the long-term risk of cardiovascular and cerebrovascular events, and even death from any cause.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>ABI is the ratio of the systolic blood pressure (SBP) measured at the ankle against one measured at the brachial artery; it was described by Winsor[<xref rid="ref4" ref-type="bibr">4</xref>] in 1950; this index was initially offered for the noninvasive diagnosis of lower-extremity PAD.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] In addition, it was shown that the ABI is an indicator of atherosclerosis at other vascular sites and can be seen as a prognostic marker for cardiovascular events, even in the absence of symptoms.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] Reperfusion itself can lead to cell damage, which is known as ischemia-reperfusion injury (IRI). Cells in organs other than the heart are very sensitive to the protective effects of IRI of other tissue.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>]</p><p>Ischemic preconditioning (IPC) is a phenomenon to avoid IRI in different vascular sites. The controlled repeated of short periods of ischemia could also protect tissues against the IRI.</p><p>IPC was first described in 1986 by Murry <italic>et al</italic>.[<xref rid="ref12" ref-type="bibr">12</xref>] as increased cellular resistance to myocardial ischemia when the heart is encountered periods of nonlethal ischemia interspersed with reperfusion. In 1993, Przyklenk <italic>et al</italic>.[<xref rid="ref13" ref-type="bibr">13</xref>] showed that increased cell resistance to ischemia also occurred in other tissues that were not directly subjected to ischemia. This phenomenon was named remote IPC (RIPC).[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref>] The remote ischemic conditioning (RIC) stimulus could be noninvasively induced using a standard blood pressure cuff placed on the upper arm or leg.[<xref rid="ref30" ref-type="bibr">30</xref>]</p><p>The protective effect by IPC has two windows of protection. The first lasts between 4 and 6 h[<xref rid="ref31" ref-type="bibr">31</xref>] and has been named early preconditioning. The second begins at 24 h lasting up to 72 h after the ischemia and reperfusion stimulus.[<xref rid="ref32" ref-type="bibr">32</xref>]</p><p>Several mechanisms show the phenomenon of RIPC, such as suppression of inflammatory genes, modulation of ATP-sensitive K<sup>+</sup> channels, nuclear factor kappa beta, nitric oxide synthesis, or free radicals pathways.[<xref rid="ref33" ref-type="bibr">33</xref>]</p><p>Based on the evidence of RIPC occurring in the tissues, we predicted that RIPC that occurs in patients with PAD and ABI &#x0003c;0.90, making the better coronary flow that increasing ABI. To test this hypothesis, we performed and compared ABI in patients with and without RIPC.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>Out of 98 investigated patients, 60 individuals were accepted for this randomized clinical trial study conducted in the Afshar Cardiovascular Hospital in Yazd between 2013 and 2014. About 15 patients did not accept the study protocol and 20 patients did not fulfill the inclusion criteria. The written and oral consent was received from all of the participants. This study was approved by the Ethics Committee of the Shahid Sadoughi University of Medical Sciences.</p><p>Diabetic patients with ABI between 0.70 and 0.90 were included. Patients with a history of cerebrovascular accident, or glomerular filtration rate lower than 30 ml/min were excluded. Physical examinations showed normal physiology of the upper limbs in all of the investigated participants.</p><p>The participants were randomly divided into two groups (intervention and control groups). The intervention group was undergoing RIPC, and the control group was tested without receiving RIPC. Although those colleagues who both measured the ABI and conducted the statistical analysis were not aware of the engaged groups, the patients were not blinded.</p><p>At first ABI was measured with blood pressure cuff, sphygmomanometer, and handheld Doppler devices (Summit Doppler L250 ABI); then calculation was performed that divided the higher of the dorsalis pedis or posterior tibial systolic pressure for each ankle by the higher of the two brachial SBP to get the ABI for each leg; next, RIPC was stimulated by giving three cycles of 5 min of ischemia followed by 5 min of reperfusion of both upper arms using a blood pressure cuff inflated to 200 mm Hg (<italic>n</italic> = 30). This was compared to no RIPC, which consisted of placing a deflated blood pressure cuff on the upper limbs (<italic>n</italic> = 30).</p><p>The participants were advised to avoid using the following substances, because of their interfering roles during the process of IPC (RIPC), within 2 h of the test: Cilostazol, sildenafil, dipyridamol, glibenclamide, nicorandyl, phenylephrine, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker &#x003c0;, statins and steroids, caffeine and alcohol.</p><sec id="sec2-1"><title>Statistical analysis</title><p>To compare the general characteristics of the two experimental groups, we used the Chi-squared or Fishers&#x02019; exact test for categorical variables. To compare ABI in each group paired <italic>t</italic>-test and between the two groups, independent <italic>t</italic>-test were used considering the two groups as an independent factor and the ABI as the repeated factor.</p><p>Data presented in the form of frequencies, means, and standard deviations. For all of the analyzes, a significance level of <italic>P</italic> &#x0003c; 0.05 was assumed.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>Totally 60 patients were analyzed in this study, including 21 males and 39 females ranging from 40 to 74 years old (average 57 years). General patient's characteristics are shown in <xref ref-type="table" rid="T1">Table 1</xref>. There were no differences between the groups regarding age, gender, hyperlipidemia, hypertension prevalence, and smoking history.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>General characteristics of participants</p></caption><graphic xlink:href="ABR-6-28-g001"/></table-wrap><p>The mean of ABI before and after intervention (RIPC) is shown in <xref ref-type="table" rid="T2">Table 2</xref>. The mean of ABI before intervention in the RIPC group was 0.82 &#x000b1; 0.055 in comparison with the control group 0.83 &#x000b1; 0.0603 (<italic>P</italic> = 0.347), so no significant differences before intervention were seen between groups.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Effect of RIPC on the ABI in the two experimental groups</p></caption><graphic xlink:href="ABR-6-28-g002"/></table-wrap><p>The mean of ABI after intervention in the RIPC group was 0.86 &#x000b1; 0.066 in comparison with the control group 0.83 &#x000b1; 0.0603 (<italic>P</italic> = 0.046). Hence, comparing the control group, the mean of ABI were greater after intervention in the RIPC group.</p><p>The mean of ABI level increased from 0.82 &#x000b1; 0.05 to 0.86 &#x000b1; 0.06 in RIPC group (<italic>P</italic> = 0.008). The intervention group showed a significant increase in the ABI in comparison with control group.</p></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>In this study, we compared the ABI before and after RIPC. Our results showed a significant increase in ABI level in diabetic patients with 0.70&#x02264; ABI &#x02264;0.90 after RIPC.</p><p>Przyklenk <italic>et al</italic>. indicated that small cycles of coronary artery occlusion in dogs maintain the myocardial cells from longer periods of ischemia.[<xref rid="ref13" ref-type="bibr">13</xref>] In addition to the cardiac muscle other organs have been shown to reply to the protective impress of RIPC, including the lungs, kidneys, liver, and skeletal muscle.[<xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref>]</p><p>Hausenloy <italic>et al</italic>. illustrated three 5 min cuff inflations and deflations of a cuff placed on the upper arm to 200 mm Hg, administered before cardiac surgery preoperative myocardial injury (43% less troponin T release) in patients undergoing elective coronary artery bypass grafting surgery.[<xref rid="ref38" ref-type="bibr">38</xref>]</p><p>Hausenloy and Yellon and Tapuria <italic>et al</italic>. reported that the mechanisms underlying the phenomenon of RIC can be noted as three interrelated events: (1) The initial events occurring in the organs in response to the RIC irritant. The application of brief episodes of RIC (Remote Ischemic Conditioning) to the remote organisms believed to produce endogenous factors which can keep them from injury. (2) The transmission of the protective signal may be multi-factorial blood factor(s), neuronal mechanisms, and systemic responses. (3) The events are occurring in the target organ or tissue which present the protective effect.[<xref rid="ref39" ref-type="bibr">39</xref><xref rid="ref40" ref-type="bibr">40</xref>]</p><p>RIPC may be mediated by humoral and neurogenic factors consisting of an early phase that starts about 24 h after RIPC and lasts for nearly 48 h.</p><p>Several humoral factors involved in RIPC phenomenon, including opioids, nitric oxide, adenosine, catecholamines, bradykinin, tumor necrosis factor-alpha, free radicals, prostaglandins and angiotensin.</p><p>Organs exhibit to ischemia have been shown to induct the protein kinase C intracellular pathways resulting in the nuclear translocation of nuclear factor kappa beta and the activation of nitric oxide synthesis. Current mechanisms involved in target organs and tissues in the early and late process of RIPC stay indeterminate; however, some studies have offered roles for mitochondrial KATP channels and neutrophils.</p><p>RIPC was also found to provoke neovascularization in the ischemic myocardium by up-regulation of vascular endothelial growth factor gene expression that limit the infarct size.[<xref rid="ref41" ref-type="bibr">41</xref>] Not withstanding its promise in animal studies, the clinical benefit of RIPC in human studies remains controversial.</p><p>Administration of KATP channel blockers prevents IPC in healthy volunteers, and IPC phenomenon is mimicked by KATP channel opening drugs.[<xref rid="ref42" ref-type="bibr">42</xref><xref rid="ref43" ref-type="bibr">43</xref>] A number of studies proposed that IRI is dependent on increased oxidative stress,[<xref rid="ref44" ref-type="bibr">44</xref><xref rid="ref45" ref-type="bibr">45</xref>] making it possible that IPC and RIPC stimulate antioxidant defenses.[<xref rid="ref46" ref-type="bibr">46</xref>]</p><p>Recent studies have discovered the RIPC that occurs in patients with PAD and low ABI[<xref rid="ref47" ref-type="bibr">47</xref><xref rid="ref48" ref-type="bibr">48</xref><xref rid="ref49" ref-type="bibr">49</xref>] might lead to the elevation of the circulating levels of some anti-inflammatory, vasodilator, or angiogenesis-inducing contents.</p><p>Repeated ischemia-reperfusion occurrence caused by physical training could be irritant for intracellular biochemical changes leading to a more valid use of oxygen by the muscle that ameliorated the endothelial function.[<xref rid="ref41" ref-type="bibr">41</xref>]</p></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusion</title><p>RIPC is a potent innate protective mechanism against ischemic injury. This study demonstrates that RIPC through using a simple, noninvasive technique including three cycles of 5 min of ischemia followed by 5 min of reperfusion of both upper arms showed a significant increase in ABI level in diabetic patients with 0.70&#x02264; ABI &#x02264;0.90. But the mechanism is not yet fully revealed; however, it has indicated a promising point in the clinical trials. No enough trial has been put forward to illustrate the effect of RIPC to decline the incidence of clinically relevant sequel of IRI. However, more powerful studies are necessary to report the case within the next 3&#x02013;4 years.</p><sec id="sec2-2"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-3" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertzer</surname><given-names>NR</given-names></name><name><surname>Beven</surname><given-names>EG</given-names></name><name><surname>Young</surname><given-names>JR</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>PJ</given-names></name><name><surname>Ruschhaupt</surname><given-names>WF</given-names><suffix>3rd</suffix></name><name><surname>Graor</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management</article-title><source>Ann Surg</source><year>1984</year><volume>199</volume><fpage>223</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">6696538</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>e21</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">19075105</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Ou</surname><given-names>FS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Prior polyvascular disease: Risk factor for adverse ischaemic outcomes in acute coronary syndromes</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><fpage>1195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">19339264</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winsor</surname><given-names>T</given-names></name></person-group><article-title>Influence of arterial disease on the systolic blood pressure gradients of the extremity</article-title><source>Am J Med Sci</source><year>1950</year><volume>220</volume><fpage>117</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">15432446</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SA</given-names></name></person-group><article-title>Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities</article-title><source>Circulation</source><year>1968</year><volume>37</volume><fpage>624</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">5649086</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>ST</given-names></name><name><surname>Hobbs</surname><given-names>JT</given-names></name><name><surname>Irvine</surname><given-names>WT</given-names></name></person-group><article-title>Ankle systolic pressure measurements in arterial disease affecting the lower extremities</article-title><source>Br J Surg</source><year>1969</year><volume>56</volume><fpage>676</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">5808379</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Criqui</surname><given-names>MH</given-names></name><name><surname>Langer</surname><given-names>RD</given-names></name><name><surname>Fronek</surname><given-names>A</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Klauber</surname><given-names>MR</given-names></name><name><surname>McCann</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Mortality over a period of 10 years in patients with peripheral arterial disease</article-title><source>N Engl J Med</source><year>1992</year><volume>326</volume><fpage>381</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1729621</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Ankle Brachial Index Collaboration</collab><name><surname>Fowkes</surname><given-names>FG</given-names></name><name><surname>Murray</surname><given-names>GD</given-names></name><name><surname>Butcher</surname><given-names>I</given-names></name><name><surname>Heald</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>197</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">18612117</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>E</given-names></name><name><surname>Gen&#x000e7;</surname><given-names>E</given-names></name><name><surname>Erkasap</surname><given-names>N</given-names></name><name><surname>Erkasap</surname><given-names>S</given-names></name><name><surname>Akman</surname><given-names>S</given-names></name><name><surname>Firat</surname><given-names>P</given-names></name><etal/></person-group><article-title>Renal protection by brief liver ischemia in rats</article-title><source>Transplantation</source><year>2002</year><volume>74</volume><fpage>1247</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12451261</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallick</surname><given-names>IH</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Winslet</surname><given-names>MC</given-names></name><name><surname>Seifalian</surname><given-names>AM</given-names></name></person-group><article-title>Ischaemic preconditioning improves microvascular perfusion and oxygenation following reperfusion injury of the intestine</article-title><source>Br J Surg</source><year>2005</year><volume>92</volume><fpage>1169</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16044427</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapuria</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>Y</given-names></name><name><surname>Habib</surname><given-names>MM</given-names></name><name><surname>Abu Amara</surname><given-names>M</given-names></name><name><surname>Seifalian</surname><given-names>AM</given-names></name><name><surname>Davidson</surname><given-names>BR</given-names></name></person-group><article-title>Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury &#x02013; A review</article-title><source>J Surg Res</source><year>2008</year><volume>150</volume><fpage>304</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19040966</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium</article-title><source>Circulation</source><year>1986</year><volume>74</volume><fpage>1124</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">3769170</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><name><surname>Ovize</surname><given-names>M</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Regional ischemic &#x02018;preconditioning&#x02019; protects remote virgin myocardium from subsequent sustained coronary occlusion</article-title><source>Circulation</source><year>1993</year><volume>87</volume><fpage>893</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7680290</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name></person-group><article-title>Efficacy of cardioprotective &#x02018;conditioning&#x02019; strategies in aging and diabetic cohorts: The co-morbidity conundrum</article-title><source>Drugs Aging</source><year>2011</year><volume>28</volume><fpage>331</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21542657</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Darling</surname><given-names>CE</given-names></name><name><surname>Dickson</surname><given-names>EW</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Cardioprotection &#x02018;outside the box&#x02019; &#x02013; the evolving paradigm of remote preconditioning</article-title><source>Basic Res Cardiol</source><year>2003</year><volume>98</volume><fpage>149</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">12883832</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Frelinger</surname><given-names>AL</given-names><suffix>3rd</suffix></name><name><surname>Linden</surname><given-names>MD</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Barnard</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an <italic>in vivo</italic> model of recurrent thrombosis</article-title><source>J Thromb Haemost</source><year>2010</year><volume>8</volume><fpage>331</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19922435</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Late preconditioning against myocardial stunning. Does aspirin close the &#x0201c;second window&#x0201d; of endogenous cardioprotection?</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><fpage>1195</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12679221</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Simkhovich</surname><given-names>BZ</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name></person-group><article-title>Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits</article-title><source>J Appl Physiol</source><year>2003</year><volume>95</volume><fpage>2563</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12909609</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>No loss in the <italic>in vivo</italic> efficacy of ischemic preconditioning in middle-aged and old rabbits</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>38</volume><fpage>1741</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11704390</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Darling</surname><given-names>CE</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: Role of inositol trisphosphate receptors and gap junctions in triggering protection</article-title><source>J Pharmacol Exp Ther</source><year>2005</year><volume>314</volume><fpage>1386</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15919762</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Darling</surname><given-names>CE</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Aging mouse hearts are refractory to infarct size reduction with post-conditioning</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>1393</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18387442</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Greiner</surname><given-names>DL</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type-1 diabetes</article-title><source>Antioxid Redox Signal</source><year>2011</year><volume>14</volume><fpage>781</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">20578962</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>291</volume><fpage>H2008</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16731645</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Maynard</surname><given-names>M</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Reduction of infarct size with D-myo-inositol trisphosphate: Role of PI3-kinase and mitochondrial K(ATP) channels</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>290</volume><fpage>H830</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16183728</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Undyala</surname><given-names>VV</given-names></name><name><surname>Wider</surname><given-names>J</given-names></name><name><surname>Sala-Mercado</surname><given-names>JA</given-names></name><name><surname>Gottlieb</surname><given-names>RA</given-names></name><name><surname>Mentzer</surname><given-names>RM</given-names><suffix>Jr</suffix></name></person-group><article-title>Acute induction of autophagy as a novel strategy for cardioprotection: Getting to the heart of the matter</article-title><source>Autophagy</source><year>2011</year><volume>7</volume><fpage>432</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">21187719</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title><italic>In vitro</italic> platelet responsiveness to adenosine-mediated &#x0201c;preconditioning&#x0201d; is age-dependent</article-title><source>J Thromb Thrombolysis</source><year>2005</year><volume>19</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15976961</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Cardioprotection with adenosine: &#x02018;A riddle wrapped in a mystery&#x02019;</article-title><source>Br J Pharmacol</source><year>2005</year><volume>145</volume><fpage>699</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">15895103</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals</article-title><source>Lasers Med Sci</source><year>2007</year><volume>22</volume><fpage>42</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17333457</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Cardioprotection via adaptation to hypoxia: Expanding the timeline and targets?</article-title><source>Basic Res Cardiol</source><year>2011</year><volume>106</volume><fpage>325</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21468767</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Mortensen</surname><given-names>UM</given-names></name><name><surname>White</surname><given-names>PA</given-names></name><name><surname>Kristiansen</surname><given-names>SB</given-names></name><name><surname>Schmidt</surname><given-names>MR</given-names></name><name><surname>Hoschtitzky</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Transient limb ischemia induces remote ischemic preconditioning <italic>in vivo</italic></article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2881</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12460865</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>GC</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name></person-group><article-title>Ischemic preconditioning of the whole heart confers protection on subsequently isolated ventricular myocytes</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2008</year><volume>294</volume><fpage>H524</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17965281</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>DK</given-names></name></person-group><article-title>Molecular mechanism of preconditioning</article-title><source>IUBMB Life</source><year>2008</year><volume>60</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">18344203</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saes</surname><given-names>GF</given-names></name><name><surname>Zerati</surname><given-names>AE</given-names></name><name><surname>Wolosker</surname><given-names>N</given-names></name><name><surname>Ragazzo</surname><given-names>L</given-names></name><name><surname>Rosoky</surname><given-names>RM</given-names></name><name><surname>Ritti-Dias</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning in patients with intermittent claudication</article-title><source>Clinics (Sao Paulo)</source><year>2013</year><volume>68</volume><fpage>495</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23778346</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>E</given-names></name><name><surname>Gen&#x000e7;</surname><given-names>E</given-names></name><name><surname>Erkasap</surname><given-names>N</given-names></name><name><surname>Erkasap</surname><given-names>S</given-names></name><name><surname>Akman</surname><given-names>S</given-names></name><name><surname>Firat</surname><given-names>P</given-names></name><etal/></person-group><article-title>Renal protection by brief liver ischemia in rats</article-title><source>Transplantation</source><year>2002</year><volume>74</volume><fpage>1247</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12451261</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkin</surname><given-names>DW</given-names></name><name><surname>Barros D&#x02019;Sa</surname><given-names>AA</given-names></name><name><surname>McCallion</surname><given-names>K</given-names></name><name><surname>Hoper</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>FC</given-names></name></person-group><article-title>Ischemic preconditioning before lower limb ischemia &#x02013; reperfusion protects against acute lung injury</article-title><source>J Vasc Surg</source><year>2002</year><volume>35</volume><fpage>1264</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12042740</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>IR</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Tsai</surname><given-names>HW</given-names></name></person-group><article-title>Transient limb ischemia induces remote preconditioning in liver among rats: The protective role of heme oxygenase-1</article-title><source>Transplantation</source><year>2006</year><volume>81</volume><fpage>1311</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16699460</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addison</surname><given-names>PD</given-names></name><name><surname>Neligan</surname><given-names>PC</given-names></name><name><surname>Ashrafpour</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>A</given-names></name><name><surname>Moses</surname><given-names>M</given-names></name><etal/></person-group><article-title>Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2003</year><volume>285</volume><fpage>H1435</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12791590</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Mwamure</surname><given-names>PK</given-names></name><name><surname>Venugopal</surname><given-names>V</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Barnard</surname><given-names>M</given-names></name><name><surname>Grundy</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>575</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17707752</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Remote ischaemic preconditioning: Underlying mechanisms and clinical application</article-title><source>Cardiovasc Res</source><year>2008</year><volume>79</volume><fpage>377</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">18456674</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapuria</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>Y</given-names></name><name><surname>Habib</surname><given-names>MM</given-names></name><name><surname>Abu Amara</surname><given-names>M</given-names></name><name><surname>Seifalian</surname><given-names>AM</given-names></name><name><surname>Davidson</surname><given-names>BR</given-names></name></person-group><article-title>Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury &#x02013; A review</article-title><source>J Surg Res</source><year>2008</year><volume>150</volume><fpage>304</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19040966</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>KJ</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name><name><surname>Regensteiner</surname><given-names>JG</given-names></name><name><surname>Hirsch</surname><given-names>AT</given-names></name></person-group><article-title>Exercise training for claudication</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1941</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12477945</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Meldrum</surname><given-names>DR</given-names></name><name><surname>Cain</surname><given-names>BS</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Harken</surname><given-names>AH</given-names></name></person-group><article-title>Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9236412</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klepzig</surname><given-names>H</given-names></name><name><surname>Kober</surname><given-names>G</given-names></name><name><surname>Matter</surname><given-names>C</given-names></name><name><surname>Luus</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Boedeker</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide</article-title><source>Eur Heart J</source><year>1999</year><volume>20</volume><fpage>439</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">10213347</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>SJ</given-names></name><name><surname>Khaliulin</surname><given-names>I</given-names></name><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>JE</given-names></name><name><surname>Heesom</surname><given-names>KJ</given-names></name><name><surname>Halestrap</surname><given-names>AP</given-names></name></person-group><article-title>Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation</article-title><source>Circ Res</source><year>2008</year><volume>102</volume><fpage>1082</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18356542</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinbrenner</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>F</given-names></name><name><surname>S&#x000e1;rv&#x000e1;ry</surname><given-names>L</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name></person-group><article-title>Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals <italic>in vivo</italic> in the rat heart</article-title><source>Cardiovasc Res</source><year>2004</year><volume>61</volume><fpage>591</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14962489</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Preconditioning the myocardium: From cellular physiology to clinical cardiology</article-title><source>Physiol Rev</source><year>2003</year><volume>83</volume><fpage>1113</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14506302</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blann</surname><given-names>AD</given-names></name><name><surname>Belgore</surname><given-names>FM</given-names></name><name><surname>McCollum</surname><given-names>CN</given-names></name><name><surname>Silverman</surname><given-names>S</given-names></name><name><surname>Lip</surname><given-names>PL</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes</article-title><source>Clin Sci (Lond)</source><year>2002</year><volume>102</volume><fpage>187</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11834138</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makin</surname><given-names>AJ</given-names></name><name><surname>Chung</surname><given-names>NA</given-names></name><name><surname>Silverman</surname><given-names>SH</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis?</article-title><source>Clin Sci (Lond)</source><year>2003</year><volume>104</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12653684</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findley</surname><given-names>CM</given-names></name><name><surname>Mitchell</surname><given-names>RG</given-names></name><name><surname>Duscha</surname><given-names>BD</given-names></name><name><surname>Annex</surname><given-names>BH</given-names></name><name><surname>Kontos</surname><given-names>CD</given-names></name></person-group><article-title>Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">18652948</pub-id></element-citation></ref></ref-list></back></article>